InnerScope Hearing Technologies signs joint collaboration & reseller agreement with GTX
- BySeeking Alpha-
InnerScope Hearing Technologies signsjoint collaboration & reseller agreement with GTX
Symbol | Exchange | Currency |
|---|
InnerScope Hearing Technologies signsjoint collaboration & reseller agreement with GTX
Amicus Therapeutics (FOLD -1.2%) announced what it called the ‘positive initial results’ for its gene therapy candidate, AT-GTX-502, currently undergoing a Phase 1/2 study in...
Amicus Optimized Transgene Show Greater Substrate Reduction than Wild Type Construct Across All Tissues and DosesFurther Validates Combining Amicus-Engineered Transgenes with...
GTx, Inc. (NASDAQ:GTXI) announced positive top-line data from a phase II study, evaluating lead pipeline candidate, enobosarm 3 mg (GTx-024), for treating postmenopausal women...
What a day for GTx, Inc. (NASDAQ:GTXI)! It had a fantastic run up on Monday, and is one of the better intraday charts I’ve seen in a while. It jumped 3.06, or 99%, to 6.15,...
GTx, Inc.’s (NASDAQ:GTXI) shares have climbed almost 99% after the company announced positive preliminary data from a phase II study, evaluating the lead pipeline candidate...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Buy | Neutral | Sell | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Buy |
| Summary | Strong Buy | Strong Buy | Buy | Strong Sell | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 154.54 | 160.11 | 151.30 | -1.90 | -1.21% | 4.93M | NYSE | |||
| 341.49 | 345.99 | 321.03 | +18.74 | +5.81% | 22.32M | NASDAQ | |||
| 22.46 | 23.26 | 22.30 | -0.69 | -2.98% | 46.07M | NYSE | |||
| 4.64 | 4.67 | 4.22 | +0.32 | +7.41% | 802.85K | NASDAQ | |||
| 16.60 | 17.16 | 16.44 | -0.27 | -1.60% | 3.79M | NYSE | |||
| 7.50 | 7.57 | 7.44 | +0.04 | +0.54% | 9.35M | NYSE | |||
| 8.24 | 8.59 | 7.87 | -0.0600 | -0.72% | 3.04M | NASDAQ | |||
| 1.05 | 1.07 | 1.00 | +0.0100 | +0.96% | 12.15M | NYSE | |||
| 9.33 | 10.00 | 9.09 | -0.57 | -5.76% | 39.95M | NYSE | |||
| 22.11 | 22.66 | 22.00 | -0.65 | -2.86% | 6.40M | NYSE | |||
| 27.27 | 27.57 | 25.46 | +1.18 | +4.52% | 50.56M | NASDAQ | |||
| 238.68 | 241.86 | 237.84 | -0.41 | -0.17% | 13.92M | NYSE | |||
| 8.81 | 10.03 | 7.24 | +1.46 | +19.86% | 244.41M | NASDAQ | |||
| 35.52 | 37.71 | 34.55 | -0.33 | -0.92% | 22.77M | NYSE | |||
| 15.10 | 15.72 | 14.57 | 0.00 | 0.00% | 14.93M | NYSE |
Oncternal Therapeutics, Inc., formerly GTX, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates for the treatment of cancers. Its pipeline includes cirmtuzumab, TK-216 and chimeric antigen receptor T-cell (CAR-T). Its cirmtuzumab product candidate is an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) monoclonal antibody. Cirmtuzumab is in a Phase-I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). TK216 is a small-molecule compound designed to inhibit the biological activity of E26 transformation-specific (ETS) oncoproteins. TK216 is being evaluated in combination with vincristine in a Phase-I clinical trial in patients with relapsed or refractory Ewing sarcoma. Its CAR-T product candidate targets ROR-1 and is in preclinical development as a treatment for hematologic cancers and solid tumors.